{"id":334162,"date":"2020-05-27T17:00:00","date_gmt":"2020-05-27T15:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/semaglutide-a-modern-glp-1-analogue-in-type-2-diabetes\/"},"modified":"2020-05-27T17:00:00","modified_gmt":"2020-05-27T15:00:00","slug":"semaglutide-a-modern-glp-1-analogue-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/semaglutide-a-modern-glp-1-analogue-in-type-2-diabetes\/","title":{"rendered":"Semaglutide &#8211; a modern GLP-1 analogue in type 2 diabetes"},"content":{"rendered":"<p><strong>People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1). Semaglutide, which mimics natural GLP-1, can compensate<sup>.1<\/sup> Like endogenous GLP-1, it normalizes blood glucose, supports weight loss, and shows fewer cardiovascular events<sup>.1,2,*<\/sup><\/strong><\/p>\n<p><!--more--><\/p>\n<p>When we eat, our intestines produce a substance called GLP-1, which stimulates the secretion of insulin in the pancreas in a glucose-dependent manner and inhibits that of glucagon. In addition, GLP-1 slows gastric emptying, increases the feeling of satiety and centrally regulates cravings. This prevents the blood sugar from rising too high.<\/p>\n<p>In patients with type 2 diabetes, too little GLP-1 is probably released or its effect is impaired. Among other things, this is why the blood glucose level of these patients rises, and consequently also the value of their long-term blood glucose, the <sub>HbA1C<\/sub>. In the long run, this triggers the well-known microvascular and macrovascular sequelae that must be prevented. A GLP-1 analogue such as Semaglutide effectively contributes to their prevention by restoring blood glucose to normal<sup>.1<\/sup><\/p>\n<p><strong>Semaglutide &#8211; a modern and potent GLP-1 analogue<\/strong><\/p>\n<p>Semaglutide is a GLP-1 analogue that is as modern as it is potent, mimicking natural GLP-1<strong>.<\/strong><sup>1 <\/sup>The optimized active ingredient is degraded in a delayed manner, thus prolonging the duration of action.<sup>3 <\/sup>This creates the possibility of once-weekly administration of semaglutide<sup>.1 <\/sup>Semaglutide can do the following:<\/p>\n<ul>\n<li>It normalizes elevated blood glucose in a glucose-dependent manner, thereby significantly lowering patients&#8217; <sub>HbA1C <\/sub><sup>.1<\/sup><\/li>\n<li>By regulating feelings of satiety and hunger, it can lead to weight loss.*<\/li>\n<\/ul>\n<p>All of this helps patients with inadequately controlled type 2 diabetes and obesity (BMI \u2265 28) achieve their treatment goals thanks to semaglutide<sup>.1<\/sup><\/p>\n<p>Also of key importance for patients with type 2 diabetes is a reduction in their cardiovascular risk. Clinical studies on cardiovascular outcome (CVOT studies) demonstrate significantly fewer cardiovascular events with semaglutide<sup>.2<\/sup> Semaglutide showed a good safety profile, comparable to safety profiles of other modern antidiabetic agents<sup>.1,2<\/sup><\/p>\n<p><strong>Ozempic\u00ae<sup>&#8211; <\/sup>harnessing the potential of Semaglutide<\/strong><\/p>\n<p>Since summer 2018, Semaglutide (<sup>Ozempic\u00ae<\/sup>) has been approved in Switzerland for patients with type 2 diabetes.<sup>1<\/sup> It has two decisive plus points for achieving the therapy goals: Very good glycemic control and significant weight reduction.<sup>1,*<\/sup> In addition, <sup>Ozempic\u00ae<\/sup> therapy in the clinical, placebo-controlled setting showed 26% fewer cardiovascular events after two years.<sup>2<\/sup><\/p>\n<p><sup>Ozempic\u00ae<\/sup> offers patients the advantage that it is applied subcutaneously only once a week<sup>.1 <\/sup>It is available as a ready-to-use pen and is easy to handle<sup>.1<\/sup> These arguments also convince patients and strengthen their compliance<sup>.4<\/sup> The success of the therapy and the prevention of possible secondary diseases depend on it.<\/p>\n<p><img decoding=\"async\" alt=\"\" data-src=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/field\/images\/bildschirmfoto_2020-05-26_um_12.16.38.png\" style=\"height:330px; width:600px\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\"><\/p>\n<div><span style=\"font-size:11px\">*Ozempic\u00ae indicated for the treatment of inadequately controlled type 2 diabetes mellitus in addition to diet and exercise, but is not indicated for weight loss or reduction of cardiovascular events<sup>.1<\/sup><\/span><\/div>\n<div>&nbsp;<\/div>\n<div><span style=\"font-size:10px\"><strong>Abbreviations: CVOT<\/strong>: Cardiovascular Outcome Trial; <strong>GLP-1<\/strong>: Glucagon-like Peptide 1.<\/span><\/div>\n<div>&nbsp;<\/div>\n<div><span style=\"font-size:10px\"><strong>References<\/strong><\/span><\/div>\n<div><span style=\"font-size:10px\">1. Ozempic\u00ae SmPC, www.swissmedicinfo.ch.<\/span><\/div>\n<div><span style=\"font-size:10px\">2 Marso et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375(19):1834-44.<\/span><\/div>\n<div><span style=\"font-size:10px\">3 Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015; 58: 7370-80.<\/span><\/div>\n<div><span style=\"font-size:10px\">4. Polonsky et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab.2011;13:144-9.<\/span><\/div>\n<div>&nbsp;<\/div>\n<div><span style=\"font-size:10px\"><strong>Limitatio<\/strong>: For the treatment of patients with type 2 diabetes, in exclusive combination therapy with metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea, when adequate glycemic control is not achieved with these oral antidiabetic agents. For treatment as combination therapy with a basal insulin alone or a combination of a basal insulin with metformin when adequate glycemic control is not achieved with these treatments. Minimum BMI 28. Additional weight loss medications are not covered by health insurance.<\/span><\/div>\n<div>&nbsp;<\/div>\n<div><span style=\"font-size:9px\"><strong><sup>Ozempic\u00ae<\/sup> Z:<\/strong> Semaglutide 1.34 mg\/ml. <strong>I: <\/strong><sup>Ozempic\u00ae<\/sup> is used to treat adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy when contraindicated or intolerant to metformin; in combination with other antihyperglycemic drugs. <strong>D:<\/strong> The starting dose of <sup>Ozempic\u00ae<\/sup> is 0.25&nbsp;mg once weekly. After 4&nbsp;weeks, the dose should be increased to 0.5&nbsp;mg once weekly. To improve blood glucose control, after at least 4&nbsp;more weeks at a dose of 0.5&nbsp;mg once per week, the dose may be increased to 1&nbsp;mg once per week. Dose adjustment is not required in the elderly, in patients with impaired renal or hepatic function. <sup>Ozempic\u00ae<\/sup> is used once a week at any time and independently of meals. <strong>AI:<\/strong> Hypersensitivity to the active substance or to one of the excipients according to &#8220;Composition&#8221;. <strong>VM:<\/strong> <sup>Ozempic\u00ae<\/sup> should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The use of GLP-1 receptor agonists may be associated with adverse gastrointestinal effects. If pancreatitis is suspected, <sup>Ozempic\u00ae<\/sup> should be discontinued. Patients receiving <sup>Ozempic\u00ae<\/sup> in combination with a sulfonylurea or insulin may be at increased risk for hypoglycemia. <sup>Ozempic\u00ae<\/sup> should be used in patients with diabetic retinopathy only under close ophthalmologic control.  <strong>IA:<\/strong> Gastric emptying delayed by Semaglutide may affect the absorption of concomitant oral medications.  <strong>UW:<\/strong> <em>Very common<\/em>: hypoglycemia when used with insulin or sulfonylurea, nausea, diarrhea.  <em>Common<\/em>: hypoglycemia when used with other OAD&#8217;s, decreased appetite, dizziness, complications of diabetic retinopathy, vomiting, abdominal pain, abdominal tightness, constipation, dyspepsia, gastritis, gastroesophageal reflux, belching, flatulence, cholelithiasis, increased lipase, increased amylase, weight loss, fatigue.  <em>Occasional<\/em>: dysgeusia, increased heart rate, injection site reactions, acute pancreatitis. Rare: Anaphylactic reaction. <strong>P:<\/strong> <sup>Ozempic\u00ae<\/sup> DualDose 0.25 mg or 0.5 mg: 1 prefilled pen of 1.5 ml; <sup>Ozempic\u00ae<\/sup> FixDose 1 mg: 2 prefilled pens of 1.5 ml, 1 prefilled pen of 3 ml (B). V4.0. For detailed information, please visit www.swissmedicinfo.ch.<\/span><\/div>\n<div>&nbsp;<\/div>\n<div><span style=\"font-size:9px\">Release number CH20OZM00083<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"<p>People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1). Semaglutide, which mimics natural GLP-1, can compensate.1 Like endogenous GLP-1, it normalizes blood glucose, supports weight loss,&hellip;<\/p>\n","protected":false},"author":12,"featured_media":97156,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Sponsored Content","footnotes":""},"category":[11384,11500,11323,11548],"tags":[],"powerkit_post_featured":[],"class_list":["post-334162","post","type-post","status-publish","format-standard","has-post-thumbnail","category-endocrinology-and-diabetology","category-news-en","category-partner-content-en","category-rx-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-18 08:07:10","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":334279,"slug":"semaglutide-un-analogue-moderne-du-glp-1-dans-le-diabete-de-type-2","post_title":"Semaglutide - un analogue moderne du GLP-1 dans le diab\u00e8te de type 2","href":"https:\/\/medizinonline.com\/fr\/semaglutide-un-analogue-moderne-du-glp-1-dans-le-diabete-de-type-2\/"},"it_IT":{"locale":"it_IT","id":334168,"slug":"semaglutide-un-moderno-analogo-del-glp-1-nel-diabete-di-tipo-2","post_title":"Semaglutide - un moderno analogo del GLP-1 nel diabete di tipo 2","href":"https:\/\/medizinonline.com\/it\/semaglutide-un-moderno-analogo-del-glp-1-nel-diabete-di-tipo-2\/"},"pt_PT":{"locale":"pt_PT","id":334142,"slug":"semaglutide-um-analogo-moderno-glp-1-na-diabetes-tipo-2","post_title":"Semaglutide - um an\u00e1logo moderno GLP-1 na diabetes tipo 2","href":"https:\/\/medizinonline.com\/pt-pt\/semaglutide-um-analogo-moderno-glp-1-na-diabetes-tipo-2\/"},"es_ES":{"locale":"es_ES","id":334152,"slug":"semaglutida-un-moderno-analogo-del-glp-1-en-la-diabetes-de-tipo-2","post_title":"Semaglutida: un moderno an\u00e1logo del GLP-1 en la diabetes de tipo 2","href":"https:\/\/medizinonline.com\/es\/semaglutida-un-moderno-analogo-del-glp-1-en-la-diabetes-de-tipo-2\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/334162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=334162"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/334162\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/97156"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=334162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=334162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=334162"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=334162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}